Discover why Incyte's strong growth trajectory and upcoming product launches make it an attractive investment with a ...

Net product revenue from Jakafi represents approximately 70% of Incyte’s total revenue, while sales from Opzelura contribute about 10%. The additional 20% is generated from royalty revenues.

Novartis/Incyte’s Jakafi (ruxolitinib) looks unlikely to be added to the list of therapies that can be used against COVID-19, after it failed to cut complications or death in a phase 3 trial.

Opzelura is under clinical development by Incyte and currently in Phase II for Unspecified Dermatological Disorders.

Wells Fargo analyst Derek Archila maintained a Hold rating on Incyte (INCY – Research Report) today and set a price target of $70.00.Stay Ahead ...

Incyte has established itself as a significant player in the hematology and oncology spaces, with its flagship product Jakafi (ruxolitinib) serving as the cornerstone of its commercial success.

Incyte has established itself as a significant player in the hematology and oncology spaces, with its flagship product Jakafi (ruxolitinib) serving as the cornerstone of its commercial success. The ...

RBC Capital raised the firm’s price target on Incyte (INCY) to $75 from $74 and keeps a Sector Perform rating on the shares as part of a ...